Physician profile
Robert E Leiba
NPI 1043202435
$1,288.12
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $65.14 · 2021: $263 · 2022: $348 · 2023: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $294.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $267.68 | 2019-2023 | Dyanavel Xr |
| Neos Therapeutics, Lp | $140.75 | 2019-2022 | |
| Corium, LLC | $123.69 | 2022-2023 | Azstarys |
| Merck Sharp & Dohme LLC | $109.70 | 2019-2023 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Ironshore Pharmaceuticals INC. | $104.80 | 2019-2023 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $100.07 | 2022-2023 | Qelbree |
| Glaxosmithkline, LLC. | $83.47 | 2019-2023 | Pediarix, Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $69.90 | 2021-2022 | |
| Pfizer INC. | $58.81 | 2022-2023 | |
| Sanofi Pasteur INC. | $45.43 | 2019-2021 | |
| Adlon Therapeutics L.P. | $44.28 | 2019-2021 | |
| Cranial Technologies, INC | $31.74 | 2022-2023 | Doc Band |
| Abbvie INC. | $29.14 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $28.36 | 2021 | |
| Sobi, INC | $20.86 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $17.66 | 2023 | Flumist Quadrivalent |
| Shire North American Group INC | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Leiba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.